Evidence map›Paper›PMID 36046750›Full record

ArticleCase reports in pulmonology2022

Treating Acute Severe Eosinophilic Asthma with IL-5 Inhibitors in ICU.

Nicolas Barbarot, Emmanuelle Nourry, Nicolas Massart, François Legay, Matthieu Debarre, Pierre Fillatre, Eric Magalhaes, Arnaud Mari, Julien Wallois, Eric Briens and 1 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in pulmonology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. The Determinants of Eosinophilia in Patients With Severe Asthma.Journal of clinical medicine research · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Nicolas BarbarotService de Réanimation, CH de SAINT BRIEUC, 10 rue Marcel Proust 22000 Saint-Brieuc, France.ORCID https://orcid.org/0000-0002-1205-1687
Emmanuelle NourryService de Réanimation, CH de SAINT BRIEUC, 10 rue Marcel Proust 22000 Saint-Brieuc, France.
Nicolas MassartService de Réanimation, CH de SAINT BRIEUC, 10 rue Marcel Proust 22000 Saint-Brieuc, France.
François LegayService de Réanimation, CH de SAINT BRIEUC, 10 rue Marcel Proust 22000 Saint-Brieuc, France.
Matthieu DebarreService de Réanimation, CH de SAINT BRIEUC, 10 rue Marcel Proust 22000 Saint-Brieuc, France.
Pierre FillatreService de Réanimation, CH de SAINT BRIEUC, 10 rue Marcel Proust 22000 Saint-Brieuc, France.
Eric MagalhaesService de Réanimation, CH de SAINT BRIEUC, 10 rue Marcel Proust 22000 Saint-Brieuc, France.
Arnaud MariService de Réanimation, CH de SAINT BRIEUC, 10 rue Marcel Proust 22000 Saint-Brieuc, France.
Julien WalloisService de Réanimation, CH de SAINT BRIEUC, 10 rue Marcel Proust 22000 Saint-Brieuc, France.
Eric BriensService de Pneumologie, CH de SAINT BRIEUC, 10 rue Marcel Proust 22000 Saint-Brieuc, France.
Stéphane JouneauService de Pneumologie, CHU de Rennes, 2 rue Henri Le Guilloux 35033 Rennes, France.
Centre Hospitalier de Saint-Brieuc · FRInstitut de Recherche en Santé, Environnement et Travail · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: About 10% of the 300 million people worldwide who suffer from asthma have a severe disease that is uncontrolled despite treatment with inhaled corticosteroids and long-acting beta agonists. The eosinophilic inflammation pathway in the respiratory tract and blood is involved and interleukin-5 (IL-5) has recently been identified as a major promotor of this pathway. The anti-IL-5 antibodies reduce the incidence of exacerbation and allowed steroid sparing in severe asthma patients but only two case reports have been published on their use in critical care. Conclusion: Anti-IL-5 antibodies are now a standard treatment for severe eosinophilic asthma that can also be useful in an emergency to treat steroid-refractory eosinophilic acute severe asthma.

Identifiers

PMID36046750
PMCPMC9420636
OpenAlexW4292560464

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.